Cooling of the scalp is a proven approach to reduce chemotherapy-induced hair loss that has been used successfully by thousands of patients worldwide with a variety of cancers and chemotherapy regimens.
Dignitana´s multi-site scalp cooling study proved that scalp cooling is a safe and effective method for reducing the risk of chemotherapy-induced hair loss in women with breast cancer. However, almost everyone can expect to experience some degree of hair loss during chemotherapy. Patients receiving chemotherapy regimens that do not produce significant alopecia are unlikely to experience benefit from scalp cooling, warranting the possible risk of scalp metastases or long-term changes in cancer prognosis. Patients receiving chemotherapy regimens that cause significant alopecia are also unlikely to see benefit of the cooling cap. The outcome is dependent on several factors including the chemotherapy regimen, dose, duration of drug infusion, chemotherapy drug metabolism and concomitant comorbidities.
The DigniCap® Scalp Cooling System received FDA Clearance in December of 2015 to specifically reduce the likelihood of chemotherapy-induced alopecia in women with breast cancer. In July of 2017, DigniCap received clearance for use with solid tumor cancers in men and women.
Please see the list of contraindications here.